Study wrapper · #1307
Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.
Editor's note
This is a consolidation rather than a surprise: the pooled effect sizes track closely with the individual STEP trials, and the genuine addition is the CRP result, which suggests inflammatory markers move alongside weight. The limits are the familiar ones for this literature — trial durations of 68 weeks or less, placebo rather than active comparators, and a serious-adverse-event confidence interval (0.76 to 1.65) wide enough to say little about rarer harms. The authors note the newer 7.2 mg STEP UP data sit outside the pooled estimate, so the headline figure should be read as reflecting mainly 2.4 mg dosing.
Plain-language abstract
Researchers pooled nine randomized trials covering 6,239 adults who were overweight or obese but did not have diabetes, comparing injected semaglutide with placebo. Participants receiving semaglutide lost about 12 percent more of their starting body weight and about 9 cm more from the waist. C-reactive protein, a general marker of inflammation, fell by roughly 41 percent. Serious adverse events were no more common than with placebo.